We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Noninvasive Sonic Beam Therapy Platform Uses Sound Waves to Destroy Liver Tumors at Sub-Cellular Level

By MedImaging International staff writers
Posted on 27 Aug 2024
Print article
Image: The Edison System delivers pulsed sound energy into the body, without any incisions or needles, to destroy tumors at sub-cellular level (Photo courtesy of HistoSonics)
Image: The Edison System delivers pulsed sound energy into the body, without any incisions or needles, to destroy tumors at sub-cellular level (Photo courtesy of HistoSonics)

Recently, the U.S. Food and Drug Administration approved a new technology known as histotripsy for treating liver tumors, including neuroendocrine tumors. Histotripsy utilizes ultrasound waves to target liver tumors noninvasively, eliminating the need for needles, radiation, or surgical interventions. In a histotripsy session, a physician employs an ultrasound probe to focus ultrasound waves precisely on the tumor, preserving the healthy surrounding tissues and blood vessels. These sound waves generate tiny bubbles in the tumor cells, which rapidly expand and collapse. This process releases energy that disintegrates the tumor cells. The body’s immune system then naturally clears away the cellular debris. Now, a sophisticated platform uses histotripsy to deliver precision-targeted, pulsed sound energy into the body without any incisions or needles. It can destroy targeted liver tumors and tissue at the sub-cellular level while allowing physicians to monitor the treatment effect in real time.

The Edison system developed by HistoSonics (Plymouth, MN, USA) is a noninvasive device that employs sound waves to destroy liver tumors. The Edison System is specifically designed for the non-invasive mechanical disruption of liver tumors, including those that are inoperable. Utilizing advanced imaging and proprietary technology, HistoSonics' image-guided sonic beam therapy system offers precise, personalized, non-invasive treatments.

The FDA’s authorization of histotripsy technology for treating liver tumors was partly based on clinical trial outcomes assessing the Edison system's effectiveness and safety in treating primary or metastatic liver tumors. The Edison is the first and only histotripsy platform in the U.S. HistoSonics plans to commercially launch the Edison system and extend its use to additional organs such as the kidneys and pancreas. As the technology becomes more accessible, patients interested in histotripsy will be able to discuss with their healthcare providers or local cancer centers about the treatment and its availability.

Related Links:
HistoSonics

New
Ultrasonic Pocket Doppler
SD1
New
Mammo 3D Performance Kits
Mammo 3D Performance Kits
Mobile Barrier
Tilted Mobile Leaded Barrier
Diagnostic Ultrasound System
MS1700C

Print article

Channels

Nuclear Medicine

view channel
Image: CD45-PET is a robust, non-invasive tool for imaging inflammation (Photo courtesy of 123RF)

Breakthrough Method Detects Inflammation in Body Using PET Imaging

Inflammation is an immune response that helps protect the body against disease. However, when inflammation becomes chronic and excessive, it can lead to various long-term conditions, including cardiovascular... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.